Healios Successfully Establishes Proprietary Universal Donor Cell Research Line

TOKYO, June 5, 2020 /PRNewswire/ -- Healios K.K. (hereinafter "the Company"; TSE: 4593),Japan's leading clinical-stage biotechnology company, has been creating Universal Donor Cells (UDCs), which are next-generation iPS cells created with gene-editing technology to engineer a low risk of immune r...